These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3831175)

  • 21. Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production.
    Lipinski M; Virelizier JL; Tursz T; Griscelli C
    Eur J Immunol; 1980 Apr; 10(4):246-9. PubMed ID: 6156843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
    Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
    J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local application of interferon to malignant brain tumors.
    Nagai M; Arai T; Kohno S; Kohase M
    Tex Rep Biol Med; 1981-1982; 41():693-8. PubMed ID: 7052705
    [No Abstract]   [Full Text] [Related]  

  • 25. [Efficacy of interferon-beta and interleukin-2 as cytokines for malignant brain tumor treatment].
    Shitara N; Nakamura H; Genka S; Takakura K
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3235-44. PubMed ID: 3318704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Regulation of cytotoxic activities of natural killer cells in nasopharyngeal carcinoma: relations to serum interferon concentrations].
    Mu M
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1991; 26(1):32-5, 63. PubMed ID: 2031731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Natural killer activity of peripheral blood lymphocytes in patients with brain tumors].
    Otsuka S; Suda K; Yamashita J; Takeuchi J; Handa H
    No Shinkei Geka; 1982 Dec; 10(12):1291-7. PubMed ID: 7170068
    [No Abstract]   [Full Text] [Related]  

  • 28. [A new experimental approach to the specific adoptive immunotherapy for malignant gliomas].
    Yamasaki T
    Nihon Geka Hokan; 1983 Nov; 52(6):783-801. PubMed ID: 6331809
    [No Abstract]   [Full Text] [Related]  

  • 29. Natural killer cell activity in oral cancer patients: II. Correlation of in-vitro modulation by leukocyte interferon with circulating interferon and interferon induction by K 562 cells.
    Gore MM; Jamkar AV; Kedarnath N; Banerjea AC; Mehta MJ; Ghosh SN
    Indian J Cancer; 1983 Mar; 20(1A):54-8. PubMed ID: 6873993
    [No Abstract]   [Full Text] [Related]  

  • 30. Natural killer activity in patients with acute viral hepatitis.
    Chemello L; Mondelli M; Bortolotti F; Schiavon E; Pontisso P; Alberti A; Rondanelli EG; Realdi G
    Clin Exp Immunol; 1986 Apr; 64(1):59-64. PubMed ID: 3089650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon--properties and action].
    Zamorska I; Kozłowski M
    Wiad Lek; 1989 Oct 1-Nov 1; 42(19-21):1086-91. PubMed ID: 2517808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced natural killer cell activity in autism.
    Warren RP; Foster A; Margaretten NC
    J Am Acad Child Adolesc Psychiatry; 1987 May; 26(3):333-5. PubMed ID: 3597287
    [No Abstract]   [Full Text] [Related]  

  • 33. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in malignant brain tumors].
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):913-20. PubMed ID: 3885862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antibody-dependent and natural cellular cytotoxicity in patients with dilated cardiomyopathy].
    Bakhov NI; Aleksandrova LZ; Osipov SG; Naumov VG; Rudnev VI
    Ter Arkh; 1986; 58(10):62-7. PubMed ID: 3798351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Regulation of the activity of human natural killer cells by autologous interferon].
    Cheknev SB; Ershov FI; Pritsker AD; Latysheva OL
    Biull Eksp Biol Med; 1994 Sep; 118(9):281-4. PubMed ID: 7819561
    [No Abstract]   [Full Text] [Related]  

  • 36. Natural killer cell and islet killer cell activities in human type 1 diabetes.
    Negishi K; Waldeck N; Chandy G; Buckingham B; Kershnar A; Fisher L; Gupta S; Charles AM
    Exp Clin Endocrinol; 1987 Aug; 89(3):345-53. PubMed ID: 3311777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect.
    Ginsburg CH; Dambrauskas JT; Ault KA; Falchuk ZM
    Gastroenterology; 1983 Oct; 85(4):846-51. PubMed ID: 6884709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depressed natural killer cell activity in acute myocardial infarction.
    Klarlund K; Pedersen BK; Theander TG; Andersen V
    Clin Exp Immunol; 1987 Oct; 70(1):209-16. PubMed ID: 3500813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
    Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
    Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
    Edwards BS; Hawkins MJ; Borden EC
    J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.